Angiex CEO Paul Jaminet Discusses Breakthrough Cancer Therapies on Life Science Success Podcast
In a recent episode of the Life Science Success podcast, Paul Jaminet, CEO of Angiex, shared insights into the company’s groundbreaking work on TM4SF1-targeted antibody-drug conjugates (ADCs) aimed at treating aggressive cancers. Jaminet highlighted Angiex’s innovative focus on targeting tumor blood vessels, offering a unique approach to combatting cancer. He also discussed the challenges in developing first-in-class therapies and the opportunities that lie ahead for Angiex as it progresses through clinical trials.
Life Science Success is hosted by Don Davis, PhD, a seasoned life-sciences executive with deep experience in guiding companies through growth and operational excellence. Dr. Davis has worked extensively in leadership, consulting, and strategic roles across the biotech and pharmaceutical sectors, making him an insightful interviewer for cutting-edge topics. His podcast features industry leaders discussing innovation, growth strategies, and the future of life sciences.
This episode provides listeners with an inside look at Angiex’s mission and its potential to revolutionize cancer treatment through targeted therapies. The Life Science Success podcast offers a platform for biotech and pharma professionals to explore key industry trends, and this episode underscores the critical role of companies like Angiex in shaping the future of cancer care.